Literature DB >> 2696564

Transforming growth factor-alpha and human cancer.

J Yeh1, Y C Yeh.   

Abstract

Human transforming growth factor-alpha TGF-alpha, a polypeptide growth factor which causes reversible transformation of normal cells, is composed of 50 amino acid residues, has a 30 to 40% amino acid homology to epidermal growth factor (EGF), and binds the EGF receptor. In human cancers, studies are beginning to show that TGF-alpha could serve as a tumor marker and as a marker for the malignant potential of a tumor. Thus far, the types of carcinomas with which abnormal TGF-alpha expression has been associated include liver, gastrointestinal, breast, skin, lung, brain and ovarian cancers. TGF-alpha may play a role in the processes involved with tumor initiation and tumor growth. In cell lines, TGF-alpha has been found to be associated with autocrine and paracrine types of cellular growth initiation and with increased levels of oncogene expression. In summary, the evidence concerning human TGF-alpha are that TGF-alpha could serve as a marker for human cancers and that an understanding of the basic actions of TGF-alpha could help to explain the self-sustaining nature of tumors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2696564     DOI: 10.1016/0753-3322(89)90083-8

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  9 in total

1.  Distribution of epidermal growth factor receptor and ligands during bronchiolar epithelial repair from naphthalene-induced Clara cell injury in the mouse.

Authors:  L S Van Winkle; J M Isaac; C G Plopper
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

2.  Identification of pro- and mature brain-derived neurotrophic factor in human saliva.

Authors:  A L Mandel; H Ozdener; V Utermohlen
Journal:  Arch Oral Biol       Date:  2009-05-20       Impact factor: 2.633

Review 3.  Biomarkers of gene expression: growth factors and oncoproteins.

Authors:  P W Brandt-Rauf
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

4.  Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes.

Authors:  A Ehrhardt; T Bartels; A Geick; R Klocke; D Paul; R Halter
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

5.  Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments.

Authors:  Weili Wang; Huizhen Zheng; Jun Jiang; Zhi Li; Dongpeng Jiang; Xiangru Shi; Hui Wang; Jie Jiang; Qianqian Xie; Meng Gao; Jianhong Chu; Xiaoming Cai; Tian Xia; Ruibin Li
Journal:  Nat Commun       Date:  2022-08-02       Impact factor: 17.694

6.  Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells.

Authors:  Gulcin Tezcan; Mohammad Alsaadi; Shaimaa Hamza; Ekaterina E Garanina; Ekaterina V Martynova; Gulshat R Ziganshina; Elina R Farukshina; Albert A Rizvanov; Svetlana F Khaiboullina
Journal:  Int J Mol Sci       Date:  2022-08-22       Impact factor: 6.208

7.  Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.

Authors:  D C Heimbrook; S M Stirdivant; J D Ahern; N L Balishin; D R Patrick; G M Edwards; D Defeo-Jones; D J FitzGerald; I Pastan; A Oliff
Journal:  J Ind Microbiol       Date:  1991-04

Review 8.  Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.

Authors:  Bao T Le; Prithi Raguraman; Tamer R Kosbar; Susan Fletcher; Steve D Wilton; Rakesh N Veedu
Journal:  Mol Ther Nucleic Acids       Date:  2018-11-20

9.  Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.

Authors:  Javier Sánchez Ramírez; Yanelys Morera Díaz; Mónica Bequet-Romero; Francisco Hernández-Bernal; Yenima Martín Bauta; Katty-Hind Selman-Housein Bernal; Ana Victoria de la Torre Santos; Mariela Pérez de la Iglesia; Lian Trimiño Lorenzo; Marta Ayala Avila
Journal:  BMC Immunol       Date:  2020-03-14       Impact factor: 3.615

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.